Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis.

ABSTRACT:

Background

The CheckMate 9DW trial showed that nivolumab plus ipilimumab (NIVO + IPI) improves overall survival over lenvatinib or sorafenib (LEN/SOR) in patients with unresectable hepatocellular carcinoma (uHCC). We evaluated the cost-effectiveness of NIVO + IPI versus LEN/SOR from payer perspectives in the United States (US) and China, explicitly aiming to inform reimbursement and price-negotiation decisions in each setting.

Methods

Based on the overall and subgroup data from the CheckMate 9DW trial, we developed a partitioned survival model to compare the clinical outcomes of NIVO + IPI versus LEN/SOR. Costs included drugs, administration, monitoring, adverse event management, and follow-up care in both the US and China. A lifetime horizon (1-month cycles) and 2024 US dol

SUBMITTER: Wu Q 

PROVIDER: S-EPMC12832771 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature